PlaqueTec recruits first ten patients in BIOPATTERN trial

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), today announced that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.

Sale of the business operations – Biotech Investments

EQS-News: PAION AG / Key word(s): Miscellaneous PAION AG: Sale of the business operations 22.12.2023 / 16:33 CET/CEST The issuer is solely responsible for the

December 23, 2023

Half yearly results as per June 30th, 2024 – Biotech Investments

Vitruvia Medical AG / Key word(s): Half Year Results/Half Year Results Vitruvia Medical AG: Half yearly results as per June 30th, 2024 25-Jul-2024 / 21:58

July 26, 2024

CMC concerns lead to FDA rejection of Theratechnologies’ concentrated version of lipodystrophy drug for HIV patients

Theratechnologies was handed a complete response letter by the FDA for the more concentrated version of its marketed lipodystrophy drug for HIV patients, Egrifta SV,

January 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.